SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study

被引：0
|
作者：
Xie, Z. [1 ]
Ye, L. [1 ]
Hu, W. [2 ]
Lv, C. [3 ]
Zhu, M. [3 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Peoples R China
[2] Anhui Med Univ, Hosp 2, Hefei, Peoples R China
[3] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Mavrilimumab (an Anti-GM-CSFRα Monoclonal Antibody) in Subjects with Rheumatoid Arthritis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
    Burmester, Gerd R.
    Weinblatt, Michael E.
    Barbarash, Olga
    Vatutin, Mykola
    Szombati, Istvan
    Stoilov, Rumen
    Matsievskaya, Galina
    Venalis, Algirdas
    Esfandiari, Ehsanollah
    Grove, Geraldine
    Saurigny, Didier
    Sleeman, Matthew A.
    Godwood, Alex
    Magrini, Fabio
    ARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 4044 - 4044
  • [12] CGRP Monoclonal Antibody LY2951742 for the Prevention of Migraine: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Dodick, D.
    Goadsby, P. J.
    Spierings, E. L.
    Scherer, J.
    Sweeney, S.
    Grayzel, D.
    HEADACHE, 2014, 54 (08): : 1430 - 1430
  • [13] CGRP Monoclonal Antibody LY2951742 for the Prevention of Migraine: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Dodick, David
    Goadsby, Peter
    Spierings, Egilius
    Scherer, Joel
    Sweeney, Steven
    Grayzel, David
    NEUROLOGY, 2014, 83 (02) : E39 - E40
  • [14] CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
    Goadsby, P.
    Dodick, D.
    Spierings, E.
    Scherer, J.
    Sweeney, S.
    Grayzel, D.
    JOURNAL OF HEADACHE AND PAIN, 2014, 15
  • [15] Safety and tolerability of Ganoderma lucidum in healthy subjects:: A double-blind randomized placebo-controlled trial
    Wicks, Sheila M.
    Tong, Robin
    Wang, Chong-Zhi
    O'Connor, Michael
    Karrison, Theodore
    Li, Shang
    Moss, Jonathan
    Yuan, Chun-Su
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2007, 35 (03): : 407 - 414
  • [16] A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis
    Bissonnette, Robert
    Papp, Kim
    Maari, Catherine
    Yao, Yihong
    Robbie, Gabriel
    White, Wendy I.
    Le, Chenxiong
    White, Barbara
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : 427 - 436
  • [17] Influence of Topical Anesthesia on Superficial Sensitivity: A Double-Blind, Randomized, Placebo-Controlled Study on 48 Healthy Subjects
    Illg, Claudius
    Krauss, Sabrina
    Kersten, Anabel
    Daigeler, Adrien
    Wenger, Andrea
    DERMATOLOGIC SURGERY, 2020, 46 (12) : 1593 - 1598
  • [18] Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
    Ruijs, Titia Q.
    Koopmans, Ingrid W.
    de Kam, Marieke L.
    van Esdonk, Michiel J.
    Koltzenburg, Martin
    Groeneveld, Geert Jan
    Heuberger, Jules A. A. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (05) : 1008 - 1019
  • [19] Erratum to: Effects of acotiamide on esophageal motility in healthy subjects: a randomized, double-blind, placebo-controlled crossover study
    Shintaro Hoshino
    Nana Takenouchi
    Yuriko Hanada
    Mariko Umezawa
    Hirohito Sano
    Noriyuki Kawami
    Yoshimasa Hoshikawa
    Tetsuro Kawagoe
    Tsutomu Nomura
    Yoshio Hoshihara
    Katsuhiko Iwakiri
    Esophagus, 2017, 14 : 272 - 273
  • [20] Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects
    Lawrence, Jody
    He, Su
    Martin, Jason
    Schoedel, Florian
    Ciarlet, Max
    Murray, Alexander V.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (08) : 2247 - 2254
12345